Next Article in Journal
Health-Related Quality of Life in Health States Corresponding to Different Stages of Perianal Fistula Associated with Crohn’s Disease: A Quantitative Evaluation of Patients and Non-Patients in Japan
Previous Article in Journal
The Burden of Hospitalisations for COVID-19 in France: A Study of All Cases in the National Insurance Claims Database in 2020
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 11
Issue 1
10.1080/20016689.2023.2166313
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Communication

The Association between Body Mass Index Groups and Metabolic Comorbidities with Healthcare and Medication Costs: A Nationwide Biobank and Registry Study in Finland

by
Aino Vesikansa
1,*,
Juha Mehtälä
1,
Katja Mutanen
2,
Annamari Lundqvist
3,
Tiina Laatikainen
3,4,5,
Tero Ylisaukko-oja
1,6,
Tero Saukkonen
2 and
Kirsi H. Pietiläinen
7
1
MedEngine Oy, Eteläranta 14, 00130 Helsinki, Finland
2
Novo Nordisk Farma Oy, Espoo, Finland
3
Finnish Institute for Health and Welfare, Helsinki, Finland
4
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
5
Joint Municipal Authority for North Karelia Social andHealth Services (Siun Sote), Joensuu, Finland
6
Center for Life Course Health Research, University of Oulu, Oulu, Finland
7
Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland & Obesity Center, Abdominal Center, Endocrinology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2023, 11(1), 2166313; https://doi.org/10.1080/20016689.2023.2166313
Submission received: 17 July 2022 / Revised: 23 December 2022 / Accepted: 3 January 2023 / Published: 18 January 2023

Abstract

ABSTRACT Background: The increasing prevalence of obesity imposes a significant cost burden on individuals and societies worldwide. Objective: In this nationally representative study, the association between body mass index (BMI) groups and the number of metabolic comorbidities (MetC) with total direct costs was investigated in the Finnish population. Study design, setting, and participants: The study cohort included 5,587 adults with BMI ≥ 18.5 kg/m2 who participated in the cross-sectional FinHealth 2017 health examination survey conducted by the Finnish Institute for Health and Welfare. Data on healthcare resource utilization (HCRU) and drug purchases were collected from national healthcare and drug registers. Main outcome measure: The primary outcome was total direct costs (costs of primary and secondary HCRU and prescription medications). Results: Class I (BMI 30.0–34.9 kg/m2) and class II–III (BMI ≥ 35.0 kg/m2) obesity were associated with 43% and 40% higher age- and sex-adjusted direct costs, respectively, compared with normal weight, mainly driven by a steeply increased comorbidity in the higher BMI groups. In all BMI groups combined, individuals with ≥2 MetCs comprised 39% of the total study population and 60% of the total costs. Conclusion: To manage the cost burden of obesity, treatment should be given equal consideration as other chronic diseases, and BMIs ≥ 30.0 kg/m2 should be considered in treatment decisions.
Keywords: body mass index; obesity; comorbidities; metabolic syndrome; direct costs; healthcare costs; medication costs body mass index; obesity; comorbidities; metabolic syndrome; direct costs; healthcare costs; medication costs

Share and Cite

MDPI and ACS Style

Vesikansa, A.; Mehtälä, J.; Mutanen, K.; Lundqvist, A.; Laatikainen, T.; Ylisaukko-oja, T.; Saukkonen, T.; Pietiläinen, K.H. The Association between Body Mass Index Groups and Metabolic Comorbidities with Healthcare and Medication Costs: A Nationwide Biobank and Registry Study in Finland. J. Mark. Access Health Policy 2023, 11, 2166313. https://doi.org/10.1080/20016689.2023.2166313

AMA Style

Vesikansa A, Mehtälä J, Mutanen K, Lundqvist A, Laatikainen T, Ylisaukko-oja T, Saukkonen T, Pietiläinen KH. The Association between Body Mass Index Groups and Metabolic Comorbidities with Healthcare and Medication Costs: A Nationwide Biobank and Registry Study in Finland. Journal of Market Access & Health Policy. 2023; 11(1):2166313. https://doi.org/10.1080/20016689.2023.2166313

Chicago/Turabian Style

Vesikansa, Aino, Juha Mehtälä, Katja Mutanen, Annamari Lundqvist, Tiina Laatikainen, Tero Ylisaukko-oja, Tero Saukkonen, and Kirsi H. Pietiläinen. 2023. "The Association between Body Mass Index Groups and Metabolic Comorbidities with Healthcare and Medication Costs: A Nationwide Biobank and Registry Study in Finland" Journal of Market Access & Health Policy 11, no. 1: 2166313. https://doi.org/10.1080/20016689.2023.2166313

APA Style

Vesikansa, A., Mehtälä, J., Mutanen, K., Lundqvist, A., Laatikainen, T., Ylisaukko-oja, T., Saukkonen, T., & Pietiläinen, K. H. (2023). The Association between Body Mass Index Groups and Metabolic Comorbidities with Healthcare and Medication Costs: A Nationwide Biobank and Registry Study in Finland. Journal of Market Access & Health Policy, 11(1), 2166313. https://doi.org/10.1080/20016689.2023.2166313

Article Metrics

Back to TopTop